NewzInnovative medications for the control of obesity and diabetes were incorporated over a year ago into the Basic Drug List of the Dominican Republic. Despite this formal inclusion, patients are still awaiting effective coverage for these treatments through health administrators (ARS).
The delay leaves patients without financial access to these newly approved therapies, highlighting a gap between official pharmaceutical listings and practical healthcare implementation within the country's medical system.
In-depth summary · AI, neutral